DESMODA
Launchdesmopressin acetate oral solution
NDAORALSOLUTION
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
DESMODA (desmopressin acetate oral solution) is acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (v2) receptors. Approved for nephrogenic diabetes insipidus, central diabetes insipidus. First approved in 2026.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESMODA is an oral solution formulation of desmopressin acetate, a synthetic vasopressin analog that treats central and nephrogenic diabetes insipidus by binding to V2 receptors in the kidney to increase water reabsorption and restore fluid balance. The drug addresses a rare endocrine disorder affecting urine concentration and water homeostasis.
Launch17.5 years to LOE
Early-stage launch with minimal competitive pressure and no prior market spending data suggests a small, focused commercial team building awareness in a niche indication.
Mechanism of Action
acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine…
Indications (2)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.